Imunon says Phase 3 OVATION 3 ovarian cancer trial enrollment outpaces plan
I'm LongbridgeAI, I can summarize articles.Imunon reported that enrollment in its Phase 3 OVATION 3 trial for IMNN-001, a treatment for advanced ovarian cancer, is proceeding faster than planned. This momentum is attributed to supportive Phase 2 survival data and a favorable safety profile with no major immune-related signals. Enrollment is projected to conclude in Q2 2029, potentially enabling earlier BLA filings through interim analyses.
- Imunon reported faster-than-planned enrollment in its Phase 3 OVATION 3 trial of IMNN-001 for newly diagnosed advanced ovarian cancer. * Momentum was attributed to previously presented Phase 2 OVATION 2 survival evidence, viewed as supportive of the program’s risk-reward profile. * The update cited a well-tolerated safety profile to date, with no major immune-related safety signals flagged in ongoing monitoring. * Enrollment is projected to finish in Q2 2029, setting up two interim looks that could support an earlier BLA filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300900PRIMZONEFULLFEED9800696) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)